The Delhi High Court has restrained Dr. Reddy’s and OneSource from selling semaglutide domestically—following Novo Nordisk’s lawsuit over alleged patent infringement tied to its blockbuster obesity drug Wegovy.
💡 But here’s the kicker: Semaglutide isn’t new.
It’s the same molecule that’s long been used for treating type 2 diabetes under Ozempic. What’s changed is the dosage and delivery format—a higher-dose injectable for weight loss—which has earned it a new IP identity and blockbuster status ($8.4B global sales in 2024).
This raises big questions in the pharma world:
🔹 Can tweaking the indication and format revive or extend IP life?
🔹 Where do we draw the line between incremental innovation and evergreening?
🔹 How can Indian pharma navigate global patents while expanding access?
For now, Indian companies can manufacture and export semaglutide, but the domestic market is on hold—until the next hearing on August 19.
🏛️ The courtroom, not the clinic, is where this next chapter will unfold.
Source: Big fat legal war bursts out ahead of Novo Nordisk’s Wegovy launch via @economictimes
About Semaglutide
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is approved by the US Food and Drug Administration (FDA) as 3 separate brand name medications—Ozempic®, Wegovy®, and Rybelsus®. Each brand name comes with its own associated indications, preparations, and dosages to consider. The Rybelsus® tablet brand demonstrates efficacy in improving glycemic control in patients with type 2 diabetes mellitus (T2DM). Ozempic® injectable brand provides an additional indication of reducing the risk of major adverse cardiovascular events in patients with and without T2DM. In a recent development, semaglutide received FDA approval under the brand name Wegovy®, which is an injection used for promoting weight loss in individuals dealing with obesity and overweight. Due to the increased complexity involved, special attention is necessary for every FDA-approved indication and current off-label use.
The numerous and evolving benefits of semaglutide are complicated due to differences in dosing and available preparations. Clinicians must obtain a firm grasp of how semaglutide may be used safely and effectively. This activity aims to provide a clear understanding of semaglutide, including its indications, benefits, mechanisms of action, potential adverse effects, monitoring recommendations, and general pharmacological characteristics. This activity also explores the essential role of the interprofessional healthcare team in improving patient outcomes with semaglutide.
Source: Semaglutide by Sharath Kommu; Philip Whitfield.
A MedicinManAI Feature
